$39.85
-0.0500 (-0.125%)
At Close: Jun 03, 2026
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical thro
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
02:49am, Tuesday, 12'th May 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG
03:44am, Monday, 27'th Apr 2026
B. Metzler seel. Sohn and Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) during the fourth quarter, according to its most recent Form 13F filing with the
Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This come
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
01:34pm, Friday, 10'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transacti
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – What’s Next?
05:52am, Thursday, 02'nd Apr 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $40.00 and last traded
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
04:14pm, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
11:11am, Wednesday, 01'st Apr 2026
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President's comments that he wants to end the war soon. While this is hardly the final straw fo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Why Centessa Stock Soared Today
09:36pm, Tuesday, 31'st Mar 2026
Centessa possesses a promising sleep medicine pipeline. The clinical-stage company's experimental therapies have blockbuster potential.
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
07:43pm, Tuesday, 31'st Mar 2026
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and N
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
03:40pm, Tuesday, 31'st Mar 2026
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion.
Sign In
Buy CNTA